Barada F A, O'Brien W, Horwitz D A
Arthritis Rheum. 1982 Jan;25(1):10-6. doi: 10.1002/art.1780250102.
The cytotoxic activities of human blood mononuclear cells against certain established cell lines were evaluated prospectively in 17 patients with rheumatoid arthritis before and after treatment with low (150 mg per week) and moderate doses (300 mg per week) of levamisole. Spontaneous or "natural" killer activity (NK) and antibody-dependent cellular cytotoxicity (ADCC) of plastic adherent cells ("monocytes") and lymphocytes were studied. We report a selective cytotoxic defect in monocyte NK and a correlation of this defect with severely active disease. The patients with the most severe defect responded to low-dose levamisole, but others with normal values did nor respond as well to treatment. This cytotoxic defect may be an important pathogenetic factor in rheumatoid arthritis and this new assay may be helpful in selecting candidates who are most likely to respond to levamisole.
前瞻性评估了17例类风湿关节炎患者在接受低剂量（每周150毫克）和中等剂量（每周300毫克）左旋咪唑治疗前后，人血单核细胞对某些既定细胞系的细胞毒性活性。研究了塑料贴壁细胞（“单核细胞”）和淋巴细胞的自发或“天然”杀伤活性（NK）以及抗体依赖性细胞毒性（ADCC）。我们报告了单核细胞NK存在选择性细胞毒性缺陷，且该缺陷与严重活动性疾病相关。缺陷最严重的患者对低剂量左旋咪唑有反应，但其他值正常的患者对治疗反应不佳。这种细胞毒性缺陷可能是类风湿关节炎的一个重要致病因素，这种新的检测方法可能有助于筛选出最有可能对左旋咪唑有反应的患者。
